Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
$14.70
+0.1%
$14.64
$6.41
$14.77
$940.21M0.84757,360 shs2.39 million shs
Amphenol Corporation stock logo
APH
Amphenol
$97.76
+0.8%
$86.34
$54.77
$98.07
$118.14B1.127.61 million shs19.78 million shs
Indivior PLC stock logo
INDV
Indivior
$13.95
+1.9%
$12.24
$7.33
$15.91
N/A0.661.21 million shs20.71 million shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
0.00%0.00%0.00%0.00%0.00%
Amphenol Corporation stock logo
APH
Amphenol
0.00%+4.24%+9.99%+46.87%+45.56%
Indivior PLC stock logo
INDV
Indivior
0.00%-0.43%+12.41%+45.92%-15.40%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Amphenol Corporation stock logo
APH
Amphenol
4.3557 of 5 stars
2.34.01.72.14.12.51.3
Indivior PLC stock logo
INDV
Indivior
1.8523 of 5 stars
1.63.00.00.02.61.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
0.00
N/AN/AN/A
Amphenol Corporation stock logo
APH
Amphenol
2.62
Moderate Buy$88.00-9.98% Downside
Indivior PLC stock logo
INDV
Indivior
3.25
Buy$15.007.53% Upside

Current Analyst Ratings Breakdown

Latest AGY, INDV, AMYT, and APH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Amphenol Corporation stock logo
APH
Amphenol
KGI Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold
6/10/2025
Amphenol Corporation stock logo
APH
Amphenol
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$90.00 ➝ $102.00
6/5/2025
Amphenol Corporation stock logo
APH
Amphenol
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$88.00 ➝ $105.00
5/30/2025
Amphenol Corporation stock logo
APH
Amphenol
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$85.00 ➝ $106.00
5/27/2025
Amphenol Corporation stock logo
APH
Amphenol
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$85.00 ➝ $100.00
5/1/2025
Amphenol Corporation stock logo
APH
Amphenol
TD Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$63.00 ➝ $70.00
4/24/2025
Amphenol Corporation stock logo
APH
Amphenol
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$78.00 ➝ $85.00
4/24/2025
Amphenol Corporation stock logo
APH
Amphenol
US Capital Advisors
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$85.00
4/24/2025
Amphenol Corporation stock logo
APH
Amphenol
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$72.00 ➝ $80.00
4/24/2025
Amphenol Corporation stock logo
APH
Amphenol
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$75.00 ➝ $85.00
(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
$222.54M4.22$0.98 per share14.98$5.58 per share2.63
Amphenol Corporation stock logo
APH
Amphenol
$15.22B7.77$2.45 per share39.85$8.17 per share11.97
Indivior PLC stock logo
INDV
Indivior
$1.19BN/A$1.82 per share7.66($2.52) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
$1M-$0.06N/A735.00N/A-8.19%1.70%0.75%N/A
Amphenol Corporation stock logo
APH
Amphenol
$2.42B$2.0647.4537.032.2315.58%27.68%13.00%7/23/2025 (Estimated)
Indivior PLC stock logo
INDV
Indivior
$2M-$0.31N/A8.16N/A-4.02%-97.29%15.74%7/24/2025 (Estimated)

Latest AGY, INDV, AMYT, and APH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/24/2025Q2 2025
Indivior PLC stock logo
INDV
Indivior
$0.25N/AN/AN/AN/AN/A
7/23/2025Q2 2025
Amphenol Corporation stock logo
APH
Amphenol
$0.66N/AN/AN/A$5.01 billionN/A
4/24/2025Q1 2025
Indivior PLC stock logo
INDV
Indivior
$0.22$0.41+$0.19$0.38$240.13 million$266.00 million
4/23/2025Q1 2025
Amphenol Corporation stock logo
APH
Amphenol
$0.52$0.63+$0.11$0.58$4.20 billion$4.81 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
N/AN/AN/AN/AN/A
Amphenol Corporation stock logo
APH
Amphenol
$0.660.68%N/A32.04%N/A
Indivior PLC stock logo
INDV
Indivior
N/AN/AN/AN/AN/A

Latest AGY, INDV, AMYT, and APH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/1/2025
Amphenol Corporation stock logo
APH
Amphenol
quarterly$0.16500.86%6/17/20256/17/20257/9/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
0.64
1.57
0.94
Amphenol Corporation stock logo
APH
Amphenol
0.66
1.99
1.36
Indivior PLC stock logo
INDV
Indivior
N/A
0.88
0.72

Institutional Ownership

CompanyInstitutional Ownership
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
71.31%
Amphenol Corporation stock logo
APH
Amphenol
97.01%
Indivior PLC stock logo
INDV
Indivior
60.33%

Insider Ownership

CompanyInsider Ownership
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
5.66%
Amphenol Corporation stock logo
APH
Amphenol
1.67%
Indivior PLC stock logo
INDV
Indivior
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
2,02063.96 million60.34 millionNot Optionable
Amphenol Corporation stock logo
APH
Amphenol
125,0001.21 billion1.19 billionOptionable
Indivior PLC stock logo
INDV
Indivior
1,051N/AN/ANot Optionable

Recent News About These Companies

Cannabis Stocks To Watch Now - June 28th
Indivior (NASDAQ:INDV) Stock Rating Upgraded by Wall Street Zen
Piper Sandler Keeps Their Buy Rating on Indivior (INDV)
Top Cannabis Stocks To Keep An Eye On - June 7th
Cannabis Stocks To Consider - June 6th
Indivior brings curtain down on turbulent 11-year run in London
Indivior: Trying To Break Addiction
Indivior backs FY25 revenue view $955M-$1.03B, consensus $1.02B

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amryt Pharma stock logo

Amryt Pharma NASDAQ:AMYT

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

Amphenol stock logo

Amphenol NYSE:APH

$97.76 +0.78 (+0.80%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$97.71 -0.04 (-0.05%)
As of 06/27/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amphenol Corporation, together with its subsidiaries, primarily designs, manufactures, and markets electrical, electronic, and fiber optic connectors in the United States, China, and internationally. It operates through three segments: Harsh Environment Solutions, Communications Solutions, and Interconnect and Sensor Systems. The company offers connectors and connector systems, including harsh environment data, power, high-speed, fiber optic, and radio frequency interconnect products; busbars and power distribution systems; and other connectors. It also provides value-add products, such as backplane interconnect systems, cable assemblies and harnesses, and cable management products; other products comprising flexible and rigid printed circuit boards, hinges, other mechanical, and production related products. In addition, the company offers consumer device, network infrastructure, and other antennas; coaxial, power, and specialty cables; and sensors and sensor-based products. It sells its products through its sales force, independent representatives, and a network of electronics distributors to original equipment manufacturers, electronic manufacturing services companies, original design manufacturers, and service providers in the automotive, broadband communication, commercial aerospace, industrial, information technology and data communication, military, mobile device, and mobile network markets. Amphenol Corporation was founded in 1932 and is headquartered in Wallingford, Connecticut.

Indivior stock logo

Indivior NASDAQ:INDV

$13.95 +0.26 (+1.90%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$13.94 -0.01 (-0.11%)
As of 06/27/2025 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.